Role of hydroxypropyl-β-cyclodextrin on freeze-dried and gamma-irradiated PLGA and PLGA–PEG diblock copolymer nanospheres for ophthalmic flurbiprofen delivery by Vega, Estefanía et al.
© 2012 Vega et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article  
which permits unrestricted noncommercial use, provided the original work is properly cited.
International Journal of Nanomedicine 2012:7 1357–1371
International Journal of Nanomedicine
Role of hydroxypropyl-β-cyclodextrin  
on freeze-dried and gamma-irradiated PLGA  
and PLGA–PEG diblock copolymer nanospheres  
for ophthalmic flurbiprofen delivery
Estefanía Vega1
M Antònia Egea1
Ana Cristina Calpena2
Marta Espina1
M Luisa García1
1Department of Physical Chemistry, 
2Department of Biopharmacy and 
Pharmaceutical Technology, Institute 
of Nanoscience and Nanotechnology, 
Faculty of Pharmacy, University  
of Barcelona, Barcelona, Spain
Correspondence: Estefanía Vega Freire 
Department of Physical Chemistry, 
Institute of Nanoscience and 
Nanotechnology, Faculty of Pharmacy, 
University of Barcelona, Av Joan XXIII s/n, 
08028 Barcelona, Spain 
Tel +34 934024552 
Fax +34 934035987 
Email evegafre7@far.ub.edu
Abstract: Poly(D,L-lactide-co-glycolide) and poly(D,L-lactide-co-glycolide) with poly(ethylene 
glycol) nanospheres (NSs) incorporating flurbiprofen (FB) were freeze-dried with several cryopro-
tective agents and sterilized by γ-irradiation. Only when 5.0% (w/v) hydroxypropyl-β-cyclodextrin 
(HPβCD) was used, a complete resuspension by manual shaking and almost identical particle 
size of the NSs was obtained after freeze-drying. In vitro drug release and ex vivo corneal per-
meation of NSs with and without HPβCD were evaluated. The presence of HPβCD resulted in a 
reduction of burst effect, providing a more sustained release of the drug. A significant decrease 
in the FB transcorneal permeation of NSs containing HPβCD was obtained, related to the slower 
  diffusion of FB observed in the in vitro results. The uptake mechanism of the NSs was examined 
by confocal microscopy, suggesting that NSs penetrate corneal epithelium through a transcel-
lular pathway. Ocular tolerance was assessed in vitro and in vivo by the Eytex™ and Draize test, 
respectively. Long-term stability studies revealed that γ-irradiated NSs stored as freeze-dried 
powders maintained their initial characteristics. Stability studies of the resuspended NSs after 
3 months of storage in the aqueous form showed that NSs were stable at 4°C, while formulations 
stored at 25°C and 40°C increased their initial particle size.
Keywords: nanospheres, poly(D,L-lactide-co-glycolide), poly(ethylene glycol), hydroxypropyl-
β-cyclodextrin, freeze-drying, γ-irradiation
Introduction
Topical application of drugs into the eye is severely limited due to the rapid and 
extensive precorneal loss caused by drainage and high tear fluid turnover. This leads 
to a very short period of drug–cornea contact time, and less than 5% of the applied 
drug actually penetrates through the cornea and is able to reach intraocular tissues 
while a major fraction of the instilled dose is often absorbed systemically via the 
conjunctiva and nasolacrimal duct, producing undesirable side effects.1,2 Thus, the 
most frequently used dosage forms, solutions and suspensions, are compromised in 
their effectiveness.
A significant effort towards new drug-delivery systems to improve ocular 
administration has been observed in recent decades.3 Successful results have been 
obtained with polymeric colloidal nanospheres (NSs). Treatment with these systems 
increases bioavailability, reduces administration frequency, and promotes drug 
targeting to specific sites.4,5 Moreover, NSs have the advantage of offering a sustained 
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release of the drug entrapped in the polymeric matrix, so 
that the required tear levels and therapeutic effects can 
be achieved.6 Although a different number of polymers 
have been investigated for formulating biodegradable NSs, 
aliphatic polyesters such as poly(D-lactic acid) (PLA) and its 
copolymers with glycolic acid (PLGA) have been extensively 
used for controlled drug-delivery systems due to many 
favorable characteristics such as good biocompatibility, their 
ability to degrade into natural metabolites, and their safety 
profile for human use.7 Surface modification of PLGA NSs 
with polyethylene glycol (PEG) or PEGylation can modulate 
the interfacial properties of the system, and thus influence 
mucoadhesion to prolong the residence time of the particles 
in the precorneal area.8
The major obstacle that limits the use of such colloidal 
systems is their instability in aqueous mediums. Aggregation 
and fusion of particles are frequently noticed after a long 
period of storage of such systems. In order to improve 
the physical and chemical stability of these systems, the 
most commonly used process, which allows converting 
solutions or suspensions into solids of sufficient stability for 
distribution and storage is freeze-drying.9
Another limiting factor concerns sterilization, which 
is essential considering their ocular use. Commonly used 
sterilization techniques, such as steam or dry heat cannot be 
used for biodegradable aliphatic polyesters such as PLGA 
since they alter the physical and chemical properties of the 
polymer. Chemical sterilization with ethylene oxide causes 
serious toxicological problems due to residual content of the 
sterilizing agent.10 As PLGA is heat- and moisture-sensitive, 
γ-irradiation appears to be the only feasible alternative 
also offering the advantages of low chemical reactivity, 
low measurable residues, and fewer variables to control.11 
A minimum absorbed dose of 25 kGy is regarded as ade-
quate for the purpose of sterilizing pharmaceutical products 
  without providing any biological validation.12 Nevertheless, 
γ-irradiation induces dose-dependent chain scission and/or 
cross-linking and concomitant molecular weight (MW) loss 
of these polymers. The decrease in the polymer MW could 
have an effect in the release rate of the drug, depending on 
the active compound entrapped in the NSs.13–15
The incorporation of cyclodextrins (CDs) such as 
hydroxypropyl-β-cyclodextrin (HPβCD) into these   polymeric 
drug-delivery systems can influence the mechanism by 
which drug is released.16,17 CDs are water-soluble cyclic 
  oligosaccharides, which can include a guest drug molecule in 
their hydrophobic cavity, allowing the solubility,   stabilization, 
and transport of hydrophobic drugs. CDs offer an additional 
tool to modulate drug release rate from PLGA and PLGA–
PEG NSs.
Flurbiprofen (FB) was used as a model drug in this study. 
FB is a nonsteroidal anti-inflammatory drug, which has been 
introduced in ocular therapy not only for the management 
of inflammatory diseases concerning ocular structures, but 
also for use during eye surgery.18 Previous studies in our 
laboratory demonstrated successful incorporation of FB in 
PLGA NSs and physical stability in the form of suspension 
was determined.4
The main objective of this study was to evaluate the 
effect of freeze-drying with various cryoprotectants and 
the effect of γ-irradiation sterilization on the properties 
of FB-loaded PLGA and PLGA–PEG NSs. Different NSs 
with and without HPβCD were obtained and in vitro release 
kinetics as well as corneal permeation studies were done to 
better understand the mechanism by which HPβCD affects 
FB release rate.
Material and methods
Materials
PLGA 75:25 (Resomer® RG756S), PLGA 50:50 (Resomer® 
RG503), and PLGA 50:50-PEG Resomer® PEG types RGP 
d 5055, RGP d 50105, and RGP d 50155 (diblock 5, 10, and 
15% PEG, respectively) were obtained from Boehringer 
Ingelheim (Ingelheim, Germany). Poloxamer 188 (P188, 
Lutrol® F68) was received from BASF (Barcelona, Spain). 
FB, D-(+)-monohydrated glucose, D-(+)-dihydrated treha-
lose, sucrose, HPβCD, and rhodamine-6G (Rd) were obtained 
from Sigma (St Louis, MO). Double distilled water was used 
after filtration in a Millipore® (Millipore, Billerica, MA) 
system. All other chemicals and reagent used in the study 
were of analytical grade.
Preparation of NSs
Nanoparticles with a matrix structure (NSs) containing 
FB were prepared by the solvent displacement technique 
described by Fessi et al19 under the optimized conditions 
determined in our previous papers.4 Briefly, an organic 
  solution of 90 mg of polymer (PLGA or PLGA–PEG) in 
25 mL of acetone containing FB (1.5 mg/mL) was poured, 
while stirring moderately, into 50 mL of an aqueous 
pH 3.5 solution containing 10 mg/mL P188. Acetone was 
then evaporated and the NS dispersion was concentrated 
to 10 mL under reduced pressure (B-480; Büchi, Flawil, 
  Switzerland). Empty NSs were prepared using the same 
procedure but with no FB added to the organic phase.
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Particle size and zeta potential
The size of NSs was determined through dynamic light 
  scattering (ZetaSizer Nano ZS; Malvern Instruments, 
Malvern, UK) and zeta potential was calculated from the 
electrophoretic mobility using the Helmholtz–Smoluchowski 
equation as reported previously.4,5
Entrapment efficiency
The FB concentration in the NSs was determined by a modi-
fied reverse-phase high-performance liquid chromatography 
(RP-HPLC) method.20 The amount of nonentrapped FB was 
separated by filtration/centrifugation technique using cen-
trifugal filter devices Ultracel YM-100 (Amicon®; Millipore) 
at 3000 rpm for 12 minutes (Sigma 301K centrifuge; Sigma, 
Barcelona, Spain). Prior to filtration/centrifugation each sam-
ple was diluted with MilliQ (Millipore) water (1:20) to avoid 
deposition of free FB (possibly crystallized in the aqueous 
phase) on the NS surface and thus measured as encapsulated. 
The RP-HPLC system consisted of a Waters 1500 pump 
(Waters, Milford, MA) with a UV-Vis 2487 detector (Waters) 
set at 254 nm. A reversed phase column (Spherisorb; Waters) 
ODS-2, Tracer (BC Aplicaciones Analíticas,   Barcelona, 
Spain) with a flow rate of 1.5 mL/minute was used. The 
mobile phase consisted of acetonitrile/water (650:350) acidi-
fied with phosphoric acid (pH 2.5).
The FB entrapment efficiency (EE) was calculated as 
indicated below:
  EE (%)
Total amount of FB Free FB
Total amount of FB
100 =
−
⋅       (1)
Freeze-drying of NSs
FB-loaded NSs were freeze-dried without cryoprotectant 
and in the presence of 5% (w/v) glucose, 5% (w/v) HPβCD, 
10% (w/v) trehalose, 10% (w/v) sucrose, and 5% (w/v) 
trehalose plus 5% (w/v) sucrose. The final concentration of 
the cryoprotectants used was chosen in order to maintain the 
tonicity of the ocular NS suspensions, which should be around 
300 mOsm/K.21 Osmolality was evaluated by freezing point 
measurements on a Fiske osmometer. The characteristics of 
the corneal surface and the lachrymal fluid pH as well as its 
buffer capacity are essential factors for ocular preparations 
since they may impact on the therapeutic effect of drugs and 
on their toxicity and stability. Tears have limited buffering 
capacity, which emphasizes the importance of the pH and buf-
fer capacity of the instilled products.22 In order to avoid these 
effects in the ocular assays presented here, test formulations 
were adjusted to tear fluid pH (7.4) using 0.1 M NaOH.
A volume of 2 mL of the NS suspension were placed 
into glass vials and frozen by immersion in liquid nitrogen 
(−196°C) and immediately freeze-dried for 24 hours at 
0.05–0.03 mbar in a LyoQuest freeze-drier (Terrassa, Spain). 
Sample reconstitution was performed by adding 2 mL of 
MilliQ water to the dried cake followed by manual shaking. 
The macroscopic appearance and the particle size of the NSs 
after reconstitution were determined.
Sterilization of NSs (γ-irradiation)
Freeze-dried NS powders (with and without FB) containing 
5% (w/v) HPβCD as a cryoprotectant agent and the raw 
PLGA and PLGA–PEG copolymers were γ-irradiated using 
60Co as the irradiation source (Aragogamma,   Barcelona, 
Spain) and received a dose of 25 kGy. According to the 
  European Pharmacopoeia this dose is adequate for the pur-
pose of sterilizing pharmaceutical products.
The influence of γ-irradiation on NS characteristics was 
evaluated by the study of particle size, zeta potential, and 
entrapment efficiency as described previously before and 
after irradiation.
Differential scanning calorimetry (DSC)
DSC analysis was performed on a Mettler Toledo DSC 823e 
System (Mettler Toledo, Barcelona, Spain). Samples (weight 
ranging from 2.65 mg to 3.00 mg) were sealed in standard 
aluminium pans and heated at a rate of 10°C/minute over a 
temperature range of 0°C–140°C. Indium (purity $ 99.95%; 
Fluka, Buchs, Switzerland) was employed to check the 
calibration of the calorimetric system. The glass transition 
temperature (Tg) of the polymer was obtained by taking the 
midpoint of the slope during glass transition. Samples were 
analyzed before and after their exposure to γ-irradiation.
In vitro release
In vitro release studies of FB from the NSs were carried out 
by the bulk equilibrium reverse dialysis bag technique.23 The 
experiments were performed under “sink conditions” to avoid 
the interference of the solubility of FB during the in vitro 
release. Briefly, 10 mL of each NS formulation was placed 
directly into 400 mL of isotonic phosphate-buffered saline 
(PBS) 0.1 M, pH 7.4 at 32°C (ocular surface temperature) 
where numerous dialysis sacs (cellulose membrane MW cut 
off 12000 D, Iberlabo, Spain) containing 1 mL of isotonic 
PBS, had been previously immersed. The dialysis sacs were 
equilibrated with isotonic PBS prior to the experiments. At 
predetermined time intervals, a dialysis bag was withdrawn 
from the stirred release medium and simultaneously the PBS 
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volume was replaced adding 1 mL of fresh buffer solution. 
The concentration of the released drug was assessed as 
described previously.
To evaluate the mechanism of release, data for the first 
60% of the drug released were plotted in the Korsmeyer–
Peppas equation24 as log cumulative percentage of drug 
released versus log time, and the exponent n was calculated 
through the slope of the straight line. Where the drug trans-
port mechanism from spherical matrices is by Fickian diffu-
sion (case I transport) when n # 0.43, if 0.43 , n , 0.85, it 
indicated anomalous (non-Fickian) transport and for values of 
n $ 0.85, case II or zero order release kinetics was indicated. 
Occasionally, values of n $ 0.85 for release from spheres 
have been observed, which has been regarded as super case 
II kinetics.
The release profile of FB was tested after NSs   sterilization. 
The similarity factor f2 was calculated from the mean release 
data before and after γ-irradiation.25
Ex vivo study
These studies used white New Zealand rabbits weighing 
1.8 kg to 2.2 kg free of any signs of ocular inflammation 
or gross abnormalities. All experiments were performed 
according to the Association for Research in Vision and 
Ophthalmology resolution for the use of animals in research 
and were approved by the local ethics committees for animal 
experimentation.
Confocal laser scanning microscopy 
(CLSM)
In order to evaluate the uptake mechanism of the NSs through 
the corneal epithelium, fluorescent NSs incorporating Rd as 
a fluorescent marker were prepared. Fifty micrograms of Rd 
was added to the acetone solution and the NSs were prepared 
as described previously.
Entrapment efficiency was calculated from the amount 
of the free Rd present in the aqueous phase of the formula-
tions (obtained by filtration/centrifugation at 3000 rpm for 
12 minutes) measuring the amount of Rd by fluorescence 
spectroscopy (λex = 523 nm, λem = 548 nm).
In vitro release experiments were performed to con-
firm that the fluorescent marker remained associated 
with the particles during the whole experiment. A bulk 
e  quilibrium reverse dialysis bag technique was performed 
(see In vitro release section). After 2 hours of incubation, 
the c  orresponding dialysis bags were withdrawn and the Rd 
concentration was determined by fluorescence spectroscopy 
(λex = 523 nm, λem = 548 nm).
A volume of 50 µL of each formulation was adminis-
tered to the cul-de-sac of fully awake conscious rabbits. 
At 2 hours postadministration, rabbits were sacrificed and 
freshly excised corneal specimens were directly mounted, 
epithelial side up, on a glass slide and examined by CLSM 
without further tissue processing.
Confocal images were taken using an Olympus Fluoview 
500 confocal microscope adapted to an inverted IX70 micro-
scope (Serveis Cientificotècnics; University of Barcelona, 
Barcelona, Spain). Samples were excited with an argon ion 
laser at 488 nm wavelength.
Corneal permeation studies
Rabbits were sacrificed by intravenous overdose of sodium 
pentobarbital and the corneas, with a 2 mm ring of sclera, 
were immediately excised and mounted in a perfusion 
  apparatus maintained at 37°C. Glutathione bicarbonate 
Ringer’s s  olution was added to the epithelial (1 mL) and the 
endothelial (3.2 mL) compartment. To ensure o  xygenation 
and agitation, an O2–CO2 (95:5) mixture was aerated 
through each compartment. Samples from the endothelial 
side were withdrawn at different times and replaced with 
fresh g  lutathione  bicarbonate Ringer’s solution. All a  nalyses 
were carried out by the RP-HPLC method previously 
described.
Each experiment was repeated six times. The apparent 
corneal permeability coefficient (Papp) was determined using 
the expression:
  P
1
AC 60
Q
t
app
o
=
⋅⋅
∆
∆
  (2)
where Q is the total amount permeated at time t, ∆Q/∆t is 
the steady-state slope of the linear portion of the plot for the 
amount of drug in the receiving chamber (Q) versus time (t), 
A is the exposed corneal surface (0.64 cm2), C0 is the initial 
concentration of drug in the donor cell, and 60 represents the 
conversion of minutes to seconds.
Determination of corneal hydration levels
Corneal hydration levels were investigated by measuring 
total water content by desiccation (gravimetric method). 
Each corneal sample was carefully removed from the scleral 
ring and weighed (WW). It was then desiccated at 100°C for 
6 hours to determine dry corneal weight (Wd). The corneal 
hydration level (%), defined as [1 − (WW/Wd)] × 100, was 
determined both on untreated corneas and corneas recovered 
from the permeation tests.
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Ocular tolerance analysis
In vitro Eytex™ test
In view of the 3R’s concept (reduction, refinement, and 
replacement), many alternative techniques such as the 
EytexTM test are already available to reduce and replace 
animal testing. In vitro screening will serve as a preliminary 
method to assess possible risk in animal studies. The EytexTM 
system (In Vitro International, Irvine, CA) is an in vitro 
method for predicting in vivo ocular irritation that uses a 
vegetable protein extracted from jack beans.26 Like the cor-
nea of the eye, this clear protein gel becomes cloudy when 
it comes into contact with an irritant. The molecules in the 
Eytex™ protein gel also have a highly organized structure, 
which is changed by irritants. The more irritant a substance 
is, the more the structure of the molecule groups is changed 
and the cloudier the gel appears. The changes in protein 
structure induced by the test product may be quantified by 
measuring the resulting changes in turbidity. Comparison 
of these optical density measurements to those produced by 
standard chemical irritants allows calculation of an “irritancy 
score” called “irritection draize equivalent” (IDE), that has 
been shown to be directly related to the potential corneal 
irritancy of the sample.27 According to the IDE score, the 
irritancy potential of the formulations may be classified 
as “minimal” (0.0–12.5), “mild” (12.5–30.0), “moderate” 
(30.0–51.0), or “severe” (.51.0). The analysis of the data 
and the IDE calculations were performed by Tecan® software 
(In Vitro International).
In vivo Draize test
Since EytexTM is not accepted as an alternative method by 
regulatory authorities,28 the in vivo Draize test was performed 
to confirm the results obtained for the in vitro irritancy test. 
In vivo eye irritation was assessed in New Zealand white 
rabbits by the Draize eye test, which is the official technique 
for the evaluation of cosmetic and pharmaceutical prod-
ucts for ocular instillation by the interpretation of Kay and 
Calandra.29,30 A single instillation of 50 µL of each sample 
was administered in one eye, using the untreated contralateral 
eye as a control. Readings were performed at 1 hour after 
sample application, then at 1, 2, 3, 4, and 7 days, respectively. 
The method provided an overall scoring system for grading 
the severity of ocular lesions involving the cornea (opacity), 
iris (inflammation degree), and conjunctiva (congestion, 
swelling, and discharge). The Draize score was determined by 
visual assessment of changes in these ocular structures. The 
mean total score (MTS) was calculated using the   following 
equation:
  MTS =+− ∑∑∑
xn xn xn 123 () () ()
525
  (3)
where x1 (n), x2 (n), and x3 (n) are the cornea, conjunc-
tiva, and iris scores, respectively, and n being the number 
of rabbits included in the ocular tolerance assay. Three 
animals were used for each product, in accordance with 
the principles of the 3R’s (reduction, refinement, and 
replacement).31
Storage conditions during stability studies
For long term experiments, samples of NS powders freeze-
dried and γ-irradiated, were stored at 4°C, 25°C, and 40°C 
protected from light. NS formulations were resuspended 
immediately and after 6 months of storage in 2 mL of isotonic 
PBS 0.1 M, pH 7.4 in order to maintain the pH and the tonic-
ity of the samples. The morphometrical properties as well as 
entrapment efficiency, pH, and tonicity of the resuspended 
formulations were evaluated after 1 and 3 months of storage 
at 4°C, 25°C, and 40°C protected from light.
Statistical analysis
Values reported are mean ± standard deviation (SD). Mean 
values of the data obtained were compared among groups 
using one-way analysis of variance and Student’s t-test for 
two-group comparison. Two-way analysis of variance was 
used to determine the effect of temperature, storage time, 
and the interaction between these factors in the long-term 
stability studies. Differences were considered significant at 
the P , 0.05 level.
Results and discussion
NSs characterization
FB-loaded NSs were prepared in order to evaluate the effect 
of the different copolymers on particle size, zeta potential, 
and entrapment efficiency. All formulations prepared showed 
suitable particle size for ocular administration lower than 
250 nm.32 The polydispersity index was lower than 0.1 indi-
cating narrow particle size distribution.
As can be seen in Table 1, NSs prepared from different 
copolymer compositions, PLGA (50:50 and 75:25) did not 
show any significant difference in particle size for blank 
NSs. Nevertheless, particle size increased for drug-loaded 
NSs prepared with the copolymer PLGA 75:25. This can 
be explained by the high ratio of lactic acid in the 75:25 
PLGA, which are more hydrophobic than the glycolic acid 
units, increasing the hydrophobic character of the copolymer, 
which has more affinity for the drug, resulting in a higher 
entrapment efficiency as well as higher particle size.
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Particle size obtained was significantly lower as the con-
tent of PEG in the copolymer increased. This could be largely 
due to the reduction in MW and increase in amphiphilic 
character of the copolymer with increasing PEG composition. 
Thus, the combined effect of MW and amphiphilicity largely 
contributed to the reduction in particle size.33
The high entrapment efficiency obtained (75%–90%) for 
both PLGA and PLGA–PEG NSs could be explained by the 
hydrophobic nature of FB. The presence of hydrophilic PEG 
segments resulted in lower entrapment efficiency values in 
comparison with PLGA NSs. FB was incorporated into NSs 
made from PLGA–PEG diblock copolymers with a fixed PEG 
block (5 KDa) and varying PLGA segments (28–95 KDa; see 
Table 1). Higher entrapment efficiency values were obtained 
for PLGA–PEG NSs as the MW of the PLGA block was 
increased due to their bigger size, which result in a smaller 
surface area for drug loss as well as a larger core for an 
increased drug entrapment.34
The results from the zeta potential show highly negative 
values for PLGA NSs due to the ionization of carboxylic end 
groups of polymer on the surface, whereas PLGA–PEG NSs 
had lower zeta potential values due to the presence of PEG 
on their surface which covers the surface charges.35
PLGA 50:50 showed a large negative zeta potential value 
in comparison with PLGA 75:25. It has been described that 
the presence of P188, the emulsifier used during the prepa-
ration of NSs, can contribute to a reduction in their surface 
charge.36 In fact, it is known that this emulsifier tends to bind 
to the NS surface through hydrophobic interactions involving 
its polyoxypropylene chains, while the hydrophilic poly-
oxyethylene chains protrude into the surrounding medium, 
thus masking the negative surface charges present in the 
NSs. In the light of these considerations, it is possible that 
a stronger interaction is established between P188 and the 
PLGA 75:25 NSs (which has a more hydrophobic surface 
due to the higher proportion of lactic acid/glycolic acid), as 
compared to the other copolymer used, thus justifying the 
lower values of zeta potential observed.
Influence of cryoprotectant  
on freeze-drying
PLGA and PLGA–PEG NSs were freeze-dried in the presence 
of a monosaccharide (5% (w/v) glucose), two disaccharides 
(10% (w/v) sucrose, 10% (w/v) trehalose), a combination of 
5% (w/v) sucrose plus 5% (w/v) trehalose, and a cyclic oligosac-
charide (5% (w/v) HPβCD). Carbohydrates are widely used for 
the protection of nanoparticles during freeze-drying.9   Adding 
cryoprotectants to the formulations resulted in no   significant 
change in morphometrical properties (data not shown), except 
for the formulations containing 5% (w/v) HPβCD, where a 
slight increase in particle size and drug loading and a decrease 
in zeta potential values was determined, which indicate the 
presence of HPβCD at the surface of the particles.37
As can be observed in Figure 1, when PLGA and PLGA–
PEG NSs were freeze-dried without cryoprotectant, full redis-
persion of the particles could not be achieved after rehydration, 
even using sonication, indicating a strong type of aggregation. 
From the results obtained, we can conclude that P188 used as 
stabilizer in the preparations of NSs did not protect formula-
tions during freeze-drying. This aggregation is explained by 
an increase in the solubility of P188 in the bulk solution during 
the freezing process. The solubility of poloxamers is higher 
in cold than in hot water, due to the hydrogen bond formation 
between the water molecules and the numerous ether type 
oxygen bonds of the poloxamers. A decrease in temperature 
favors the solvation of the poloxamer by increasing hydration 
Table 1 Physicochemical properties and entrapment efficiency of PLGA and PLGA–PEG NSs with and without FB
NS composition MW (KDa) Size ± SD (nm) PI ± SD ζ-potential ± SD (mV) EE ± SD (%)
PLGA 75:25 98 202.0 ± 1.8 0.076 ± 0.009 −25.7 ± 1.3 –
PLGA 75:25 + FB 232.8 ± 1.9 0.048 ± 0.045 −25.8 ± 1.2 94.6 ± 0.4
PLGA 50:50 34 205.3 ± 1.4 0.051 ± 0.003 −34.0 ± 0,5 –
PLGA 50:50 + FB 197.5 ± 1.4 0.062 ± 0.022 −33.5 ± 0.4 90.3 ± 3.2
PLGA 50:50–PEG 5% 95 PLGA + 5 PEG 146.8 ± 2.1 0.081 ± 0.014 −22.5 ± 0.3 –
PLGA 50:50–PEG 5% + FB 147.7 ± 1.8 0.052 ± 0.043 −22.2 ± 0.2 87.7 ± 3.7
PLGA 50:50–PEG 10% 45 PLGA + 5 PEG 121.3 ± 0.9 0.090 ± 0.002 −17.3 ± 0.4 –
PLGA 50:50–PEG 10% + FB 123.3 ± 1.6 0.094 ± 0.063 −17.0 ± 0.6 80.5 ± 5.0
PLGA 50:50–PEG 15% 28 PLGA + 5 PEG 90.2 ± 0.9 0.094 ± 0.021 −12.8 ± 0.2 –
PLGA 50:50–PEG 15% + FB 96.8 ± 0.8 0.085 ± 0.019 −12.3 ± 1.7 75.0 ± 2.4
Note: Mean ± SD, n = 3.
Abbreviations: EE, entrapment efficiency; FB, flurbiprofen; MW, molecular weight of PLGA and PLGA–PEG copolymers used for NS preparations; NSs, nanospheres; 
PI,  polydispersity  index;  PLGA,  Poly(D,L-lactide-co-glycolide);  PLGA–PEG,  poly(D,L-lactide-co-glycolide)  with  poly(ethylene  glycol);  SD,  standard  deviation;  ζ-potential,   
zeta potential.
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of the polyethylene oxide shell and polypropylene blocks, thus 
the dynamic motion of the surface attached chains is broken 
and the latter tend to remain in the bulk solution.38
As shown in Figure 1, when glucose, trehalose, sucrose, 
and a combination of trehalose and sucrose were used, NSs 
resuspension was achieved using sonication, but particle 
size was increased and trace amounts of aggregates were 
observed, although small in comparison with NSs without 
cryoprotectant. Only NSs containing 5% (w/v) HPβCD did 
not show signs of aggregation and were easily reconstituted 
by manual shaking, and the size measurement demon-
strated almost identical mean particle size before and after 
freeze-drying. The cyclic structure of these oligoglucoside 
compounds ensured a better adsorption onto the NS surface 
during the sublimation of the aqueous phase. These results 
are in accordance with those obtained by other authors.39
Freeze-drying may generate many stresses that could 
destabilize colloidal suspension of NSs, especially, the stress 
of freezing and dehydration. During the freezing step there 
are dramatic changes in frozen NS formulations. The ice 
crystallization leads to a phase separation and cryoconcen-
tration of NSs. Such modification can induce aggregation of 
NSs. Suitable cryoprotectants can prevent such damage. Such 
excipients can be easily vitrified during freezing and form 
a protective amorphous matrix around NSs. These sugars 
are known to vitrify at a specific temperature denoted Tg’ 
(glass transition temperature of maximally cryoconcentrated 
  solutions). In general, freezing must be carried out below Tg’ of 
a frozen sample to ensure the total solidification of the sample. 
HPβCD forms a glassy state at low temperature (Tg’ measured 
by DSC was about −15°C), a higher value than the other sac-
charides under study.40 These results suggest that lower con-
centrations of HPβCD are needed to maintain particle size. 
HPβCD forms an amorphous matrix into which the PLGA 
and PLGA NSs are interdispersed. All particles are well 
separated throughout the matrix, suggesting the formation 
of hydrogen bonding between the sugar and the polar groups 
at the surface of the NSs protecting them during freezing 
and dehydration. The immobilization of NSs within a glassy 
matrix of cryoprotectant prevent aggregation of NSs.41
Thus, the stabilizing effect of low MW mono- and disac-
charides, was not sufficient at the sugar concentration tested, 
limited by the tonicity of the NS suspensions for ophthalmic 
administration, which should be around 300 mOsm/K. Results 
obtained by other authors showed that only 20% (w/v) sucrose 
exerted an acceptable cryoprotectant effect on PLGA NSs.42
Influence of γ-irradiation  
on the physicochemical  
characteristics of polymers and NSs
Freeze-dried NS powders (with and without FB) containing 
5% (w/v) HPβCD as a cryoprotectant agent and the raw 
PLGA and PLGA–PEG copolymers were γ-irradiated and the 
morphometrical properties before and after sterilization were 
evaluated as can be observed in Table 2. The results obtained 
demonstrate that γ-irradiation did not seem to have any effect 
on particle size, zeta potential, and entrapment efficiency. 
Reconstitution was achieved by manual shaking.
DSC studies were performed in the raw polymers, and 
empty and drug-loaded NSs before and after sterilization 
(Table 3) in order to investigate the physical state of the drug 
in the NSs, since this aspect could influence the in vitro and 
in vivo release of the drug from these systems.
PLGA 75:25 raw copolymer exhibited higher Tg values 
(59.44°C) relative to PLGA 50:50 (54.18°C). The Tg of 
PLGA copolymers increase with increasing lactide content 
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in the copolymer composition and when the MW of the 
polymer increases, possibly due to a diminution of polymer 
chain mobility and consequently an increase of Tg.43
Results show that the Tg values of PLGA–PEG copo-
lymers were lower than that obtained for PLGA. Tg values 
of polymers depend on their MW and their composition. 
Although PLGA–PEG (5%–15% of PEG content; see 
Table 1) copolymers have higher MW than PLGA, they 
contain PEG chains that cause a slight reduction of the Tg 
values of the polymers, due to the plasticizing effect exerted 
by PEG, which is based on the reduction of the attractive 
forces among the polymer chains.44
When empty NSs were tested, the Tg values obtained 
were similar to that obtained for the polymers alone, reveal-
ing that production process did not affect the copolymer 
structure. Nevertheless, when the polymer was formulated 
in NSs containing FB, a lower Tg was found, probably due 
to the interaction between FB and the polymer, leading 
to a plasticization of the polymer.45 The melting peak of 
FB (114.9°C) was not detected in all NSs analyzed, sug-
gesting the absence of free crystalline FB. It can thus be 
concluded that FB formulated in PLGA and PLGA–PEG 
NSs was in an amorphous or disordered crystalline phase 
of a molecular dispersion or a solid solution state in the 
polymer matrix.
As shown in Table 3, γ-irradiation of raw polymers 
and empty NSs caused a small reduction in the Tg values 
(P , 0.05). This effect may be due to the chain scission of 
the polymers during the sterilization process, which led to a 
decrement of MW of polymers and consequently an increase 
of free volume and chain mobility.46 Nevertheless, Tg values 
of sterilized and nonsterilized FB-loaded NSs were similar 
(P . 0.05). FB incorporated into the polymeric matrix seems 
to play an important role on NSs behavior after irradiation, 
improving PLGA and PLGA–PEG NSs stability.
The evaluation of the possible degradation of FB by 
irradiation was performed by HPLC. The chromatograms 
extracted from the irradiated samples were similar to those 
of the nonirradiated samples and did not reveal any evidence 
of the drug radiolysis at the irradiation dose tested.
In vitro release of NSs
Saturation concentration of FB in the release medium 
(  isotonic PBS 0.1 M, pH 7.4) at 32°C is 4.86 ± 0.3 mg/mL, 
Table 3 Values of glass transition temperature for raw polymer, 
empty NSs, and FB-loaded NSs before and after γ-irradiation
Tg (°C)
Nonirradiated γ-irradiated
PLGA 75:25 raw polymer 59.44 52.84*
PLGA 75:25 NS  57.62 53.51*
PLGA 75:25 + FB NS 47.25 47.44
PLGA 50:50 raw polymer 54.18 49.78*
PLGA 50:50 NS 49.05 46.43*
PLGA 50:50 + FB NS 44.48 45.87
PLGA 50:50–PEG 5% raw polymer 49.09 34.58*
PLGA 50:50–PEG 5% NS 48.45 43.76*
PLGA 50:50–PEG 5% + FB NS 41.41 42.54
PLGA 50:50–PEG 10% raw polymer 46.09 35.99*
PLGA 50:50–PEG 10% NS 43.33 37.95*
PLGA 50:50–PEG 10% + FB NS 42.45 40.51
PLGA 50:50–PEG 15% raw polymer 43.82 33.85*
PLGA 50:50–PEG 15% NS 42.53 38.56*
PLGA 50:50–PEG 15% + FB NS 39.55 38.78
Note: *P , 0.05 against nonirradiated samples.
Abbreviations: FB, flurbiprofen; NSs, nanospheres; PLGA, Poly(D,L-lactide-co-
glycolide);  PLGA–PEG,  poly(D,L-lactide-co-glycolide)  with  poly(ethylene  glycol);   
Tg, glass transition temperature.
Table 2 Physicochemical properties and entrapment efficiency of freeze-dried PLGA and PLGA–PEG NSs with and without FB before 
and after γ-sterilization with 5% (w/v) hPβCD
 NS composition Size ± SD (nm) PI ± SD ζ-potential ± SD (mV) EE ± SD (%)
Before* After Before* After Before* After Before* After
PLGA 75:25 213.3 ± 1.3 213.9 ± 2.5 0.052 ± 0.034 0.082 ± 0.020 −23.3 ± 2.1 −22.9 ± 1.3 – –
PLGA 75:25 + FB 234.3 ± 2.1 232.9 ± 4.0 0.080 ± 0.007 0.061 ± 0.013 −23.1 ± 0.5 −22.5 ± 0.8 97.1 ± 1.2 97.0 ± 1.4
PLGA 50:50 207.9 ± 0.3 209.4 ± 5.0 0.036 ± 0.015 0.081 ± 0.020 −31.6 ± 2.1 −32.1 ± 1.4 – –
PLGA 50:50 + FB 206.1 ± 2.1 204.9 ± 4.0 0.083 ± 0.027 0.101 ± 0.034 −31.7 ± 1.1 −31.6 ± 1.4 91.7 ± 3.7 92.5 ± 2.1
PLGA 50:50–PEG 5% 153.2 ± 1.6 151.5 ± 2.8 0.124 ± 0.008 0.110 ± 0.015 −20.5 ± 0.4 −19.9 ± 1.2 – –
PLGA 50:50–PEG 5% + FB 150.4 ± 1.6 150.2 ± 1.4 0.105 ± 0.009 0.118 ± 0.009 −20.4 ± 0.1 −20.1 ± 2.0 90.7 ± 1.8 90.4 ± 0.8
PLGA 50:50–PEG 10% 126.6 ± 0.8 124.5 ± 0.7 0.073 ± 0.011 0.084 ± 0.007 −15.2 ± 0.5 −15.8 ± 3.2 – –
PLGA 50:50–PEG 10% + FB 128.8 ± 1.2 124.9 ± 0.6 0.084 ± 0.014 0.089 ± 0.020 −14.9 ± 0.1 −13.9 ± 0.3 83.3 ± 2.0 83.5 ± 3.4
PLGA 50:50–PEG 15%   94.5 ± 0.4   94.5 ± 0.4 0.115 ± 0.010 0.130 ± 0.012 −10.5 ± 2.3 −10.7 ± 1.3 – –
PLGA 50:50–PEG 15% + FB   96.2 ± 1.1   95.7 ± 0.3 0.115 ± 0.014 0.131 ± 0.004 −10.4 ± 1.0 −9.9 ± 1.4 79.6 ± 0.9 80.3 ± 1.6
Notes: Mean ± SD, n = 3. *Freeze-dried NSs containing 5% (w/v) hPβCD (P . 0.05 in size, ζ-potential and EE against nonirradiated samples).
Abbreviations: EE, entrapment efficiency; FB, flurbiprofen; HPβCD, hydroxypropyl-β-cyclodextrin; NSs, nanospheres; PI, polydispersity index; PLGA, Poly(D,L-lactide-co-
glycolide); PLGA–PEG, poly(D,L-lactide-co-glycolide) with poly(ethylene glycol); SD, standard deviation; ζ-potential, zeta potential.
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which demonstrates that the “sink conditions” were main-
tained during the whole experiment.
The cumulative in vitro release profiles of PLGA and 
PLGA–PEG NSs are given in Figure 2. For all formulations, 
release occurred in two phases: an initial burst release, attrib-
uted to the fraction of drug that was adsorbed on the surface 
of the NSs, followed by a more gradual release. Release was 
slower for PLGA 75:25 than PLGA 50:50 (34.4% ± 2.8% 
and 64.9% ± 1.1%, respectively) in the first hour of study, 
probably due to the more hydrophobic nature due to increase 
in lactide content of the polymer and high drug loading of the 
FB due to the higher affinity of the drug with the   polymer, 
which results in a slower diffusion of the FB out of the poly-
mer matrix and showing a more sustained release.
As can be observed PLGA–PEG NSs resulted in signifi-
cantly faster release of the drug from the NSs compared with that 
from PLGA samples. This might be due to porous morphology 
of the PLGA–PEG NSs and the drug being partially entrapped 
within the PEG chains, which facilitates FB release.47
The effect of incorporating HPβBC in PLGA and PLGA–
PEG NSs was evaluated. The addition of HPβBC significantly 
decreased burst release of FB probably due to the interac-
tion of HPβBC onto the surface of the NSs, which creates a 
diffusional resistance to the release of the drug creating an 
additional barrier to the release of the drug.37
In this study, the Korsmeyer–Peppas model was used 
to analyze the release data. The diffusional exponent (n), 
determination coefficient (r2), and the release rate constant 
(k) obtained are summarized in Table 4. Good determination 
coefficients (r2) between 0.9404 and 0.9989 were obtained. 
It was shown that the exponent n values for the FB release 
from NSs without HPβCD were less than 0.43, suggesting 
Fickian release behavior.48
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Figure 2 In vitro release profiles of FB from: (A) PLGA and PLGA–PEG NSs, 
(B) PLGA and PLGA-NSs in the presence of 5% (w/v) hPβCD, (C) PLGA and 
PLGA-NSs in the presence of 5% (w/v) hPβCD after sterilization.
Note: Error bars represent ± SD.
Abbreviations:  FB,  flurbiprofen;  HPβCD,  hydroxypropyl-β-cyclodextrin;  NS, 
nanospheres;  PLGA,  Poly(D,L-lactide-co-glycolide);  PLGA–PEG,  poly(D,L-lactide-
co-glycolide) with poly(ethylene glycol); SD, standard deviation.
Table 4 Release kinetics obtained after fitting FB release data from NSs into Korsmeyer–Peppas model
NS composition Korsmeyer–Peppas model Transport mechanism
r2 k ± SD (h-n) n ± SD
PLGA 75:25 0.9637 1.64 ± 0.38 0.28 ± 0.04 Fickian diffusion
PLGA 50:50 0.9451 4.59 ± 0.45 0.16 ± 0.02 Fickian diffusion
PLGA 50:50–PEG 5% 0.9404 5.02 ± 0.51 0.16 ± 0.02 Fickian diffusion
PLGA 50:50–PEG 10% 0.9563 5.65 ± 0.44 0.15 ± 0.01 Fickian diffusion
PLGA 50:50–PEG 15% 0.9511 5.49 ± 0.49 0.16 ± 0.02 Fickian diffusion
PLGA 75:25/hPβCD 0.9922 0.21 ± 0.03 0.56 ± 0.03 Non-Fickian or anomalous diffusion
PLGA 50:50/hPβCD 0.9945 0.15 ± 0.02 0.68 ± 0.03 Non-Fickian or anomalous diffusion
PLGA 50:50–PEG 5%/hPβCD 0.9950 0.15 ± 0.02 0.68 ± 0.03 Non-Fickian or anomalous diffusion
PLGA 50:50–PEG 10%/hPβCD 0.9949 0.26 ± 0.03 0.60 ± 0.02 Non-Fickian or anomalous diffusion
PLGA 50:50–PEG 15%/hPβCD 0.9989 0.23 ± 0.01 0.62 ± 0.01 Non-Fickian or anomalous diffusion
Note: Mean ± SD, n = 3.
Abbreviations: FB, flurbiprofen; HPβCD, hydroxypropyl-β-cyclodextrin; k, release rate constant; n, diffusional exponent; NSs, nanospheres; PLGA, Poly(D,L-lactide-co-
glycolide); PLGA–PEG, poly(D,L-lactide-co-glycolide) with poly(ethylene glycol); SD, standard deviation.
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However, when HPβCD was incorporated into the for-
mulations, results obtained show anomalous (non-Fickian) 
release.49 This may be due to the reservoir effect of HPβCD, 
which causes a sustained release of FB.
The release profile of γ-irradiated NSs showed a similar 
biphasic pattern in both irradiated and nonirradiated samples. 
Both profiles were compared using the similarity factor (f2), 
which allows determination of dissolution profiles (it was 
estimated that a value for the similarity factor between 50 
and 100 indicated similarity between curves). The f2 values 
obtained for PLGA 75:25, PLGA 50:50, PLGA 50:50–PEG 
5%, PLGA 50:50–PEG 10%, and PLGA 50:50–PEG 15% 
were 73.87, 56.12, 56.95, 57.11, and 58.05, respectively, 
indicating that the curves were similar and overlapping. These 
results demonstrated that γ-irradiation did not influence drug 
release kinetics.
Ex vivo study
CLSM
NSs prepared using Rd showed high entrapment efficiency 
(around 98% for all formulations) and the in vitro release 
experiment indicated that only negligible amounts of Rd were 
released from NSs in a 2-hour period (10%). Consequently, 
Rd is an adequate marker that remains associated to the 
system for extended periods of time.
The images obtained (Figure 3) by CLSM of the   rabbit 
corneal epithelium (ex vivo study) exposed to Rd-NSs 
(PLGA and PLGA–PEG NSs with and without HPβCD), 
showed that the fluorescent spots are uniformly distributed 
inside the cells, rather than in the intercellular spaces, thus 
suggesting that the NSs penetrate the corneal epithelium 
through a transcellular pathway. Control images in the 
absence of NSs did not show fluorescent in the cells (data 
not shown). These results are in accordance with those 
reported previously for poly(alkylcyanoacrylate)50 and 
poly-ε-caprolactone nanoparticles.51 The mechanism of cel-
lular internalization is thought to occur predominantly by 
adsorptive endocytosis indicated by nonspecific interactions 
between nanoparticles and cell membranes in the first layers 
of the corneal epithelium.52
Corneal permeation studies
In order to evaluate the capacity of the developed systems to 
enhance the corneal penetration of FB, an ex vivo study was 
performed (Figure 4). The apparent corneal permeability coef-
ficient (Papp) and hydration level of each formulation is shown 
in Table 5. Results for PLGA 75:25, free FB in isotonic PBS, 
and commercial eyedrops (Ocufen®) were obtained from 
  previous studies.5 PLGA and PLGA–PEG NSs containing 1.5% 
FB (w/v) showed Papp values (Table 5) higher than those obtained 
previously for free FB in isotonic PBS and commercial eyedrops 
(Ocufen®) with 0.3% (w/v) FB (2.48 ± 1.06 × 10−6 cm ⋅ s−1 and 
11.28 ± 5.26 × 10−6 cm ⋅ s−1, respectively).
The Papp values were found to be similar for the NSs 
prepared with different ratios of lactic acid/glycolic acid 
(P . 0.05). Both PLGA 75:25 and PLGA 50:50 are useful 
Figure 3 Confocal images of a cross-section of the corneal epithelium at depth of 
10 µm after 2 hours of incubation with: (A) Rd-PLGA NS; (B) Rd-PEG-PLGA NSs; 
(C) Rd-NSs containing 5% (w/v) hPβCD.
Abbreviations: hPβCD, hydroxypropyl-β-cyclodextrin; NS, nanospheres; PLGA, 
Poly(D,L-lactide-co-glycolide);  PLGA–PEG,  poly(D,L-lactide-co-glycolide)  with 
poly(ethylene glycol); Rd, rhodamine-6G.
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in terms of increasing the penetration of FB and no influence 
of the composition of the copolymer was observed.
The effect of PEG on the transcorneal permeation of FB 
was evaluated as shown in Figure 4. PEG–PLGA NSs showed 
no differences compare to PLGA NSs (P . 0.05). The pres-
ence of the PEG steric barrier is mainly due to prevent the 
adsorption of enzymes and proteins, such as lysozyme, an 
enzyme that is highly concentrated in the mucus ocular layer 
and mucus components, thereby enhancing the stability in 
contact with mucosal fluids and, hence, improving the inter-
action of these colloidal systems with the ocular mucosa.53 
However, the ex vivo study was performed in the absence of 
enzymes and mucin and, consequently, the expected positive 
effect of PEG coating was not evident.54 Results obtained 
in vivo by other authors demonstrated the increase in ocular 
bioavailability by PEG coating of these colloidal systems.8
Results showed that there was a significant decrease in 
Papp when HPβCD was added to the formulations. This might 
be related to the slower diffusion of drug from NSs as can be 
observed from the results obtained in the in vitro release study 
giving a more sustained release of the drug from the colloidal 
systems, due to the complex formation between nonentrapped 
FB and the HPβCD.55,56 The results suggest two mechanisms 
of penetration of the corneal membrane: NSs containing the 
entrapped drug penetrate the first layers of the corneal epithelium 
as demonstrated in the images obtained by CLSM.   However, 
free FB not entrapped into the polymeric network forms a 
complex with HPβCD. In this latter case, HPβCD acts as a true 
carrier by keeping FB and delivering the drug to the surface of 
the ocular barrier where FB, which is a small (MW = 244 D) 
and highly hydrophobic drug, penetrates through the cornea 
mainly by passive transcellular diffusion.57 The cornea has low 
affinity for the hydrophilic HPβCD molecules and therefore 
they remain in the aqueous exterior membrane.58 Corneal 
hydration is frequently used as a parameter to evaluate 
damage to this tissue. The normal cornea has a hydration 
level of 76%–80%.57 A hydration level that is 3%–7% units 
above the normal value denotes damage to the epithelium or 
endothelium.59 As shown in Table 5, corneal hydration after 
the studies was not increased by more than 3%, indicating that 
the formulations did not cause any damage to the epithelium 
or endothelium during the studies.
Ocular tolerance
In vitro EytexTM test
FB-loaded NSs showed IDE values ranging between 7.8 and 
9.7 and was classified into the rank of “minimal” irritancy.
Table 5 Corneal hydration levels and permeation coefficients of 
different NS formulations containing FB
NS composition HL (%) Papp (×10−6 cm ⋅ s-1)
PLGA 50:50 77.95 ± 1.06 17.72 ± 2.54
PLGA 50:50–PEG 5% 79.01 ± 3.25 17.15 ± 5.12
PLGA 50:50–PEG 10% 78.43 ± 1.99 17.60 ± 4.65
PLGA 50:50–PEG 15% 78.64 ± 2.67 17.07 ± 3.14
PLGA 75:25/hPβCD 79.15 ± 2.15 8.73 ± 3.97
PLGA 50:50/hPβCD 78.16 ± 2.65 8.80 ± 3.62
PLGA 50:50–PEG 5%/hPβCD 79.46 ± 1.68 9.67 ± 1.95
PLGA 50:50–PEG 10%/hPβCD 77.56 ± 1.04 9.19 ± 1.39
PLGA 50:50–PEG 15%/hPβCD 78.26 ± 0.95 8.45 ± 3.97
Note: Mean ± SD, n = 6.
Abbreviations:  FB,  flurbiprofen;  HL,  corneal  hydration  level;  HPβCD, 
hydroxypropyl-β-cyclodextrin;  NS,  nanospheres;  Papp,  permeation  coefficient; 
PLGA,  Poly(D,L-lactide-co-glycolide);  PLGA–PEG,  poly(D,L-lactide-co-glycolide) 
with poly(ethylene glycol); SD, standard deviation.
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Figure 4 Permeation of FB through isolated rabbit cornea from PLGA and PLGA–PEG NSs with and without hPβCD.
Note: Error bars represent ± SD.
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In vivo Draize test
Since a single in vitro test could not mimic the entire 
situation in vivo, tolerance studies on male albino rabbits 
were performed. Topical application of formulations to rabbit 
eyes showed no sign of toxicity or irritation to the external 
ocular tissues (MTS = 0 in all cases) after the Draize test, 
which are in accordance with the results obtained by the 
Eytex™ test.
Long term stability of NSs
To ensure NSs stability of the γ-irradiated and freeze-dried 
NS powders, a storage stability study was performed. 
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Figure 5 (A and B) Particle size, PI, and ζ-pot of the sterilized NS powders stored at 4°C, 25°C, and 40°C after 6 months of storage; (C and D) Particle size, PI, and ζ-pot 
of the rehydrated samples after 1 and 3 months of storage at 4°C, 25°C, and 40°C.
Notes: Error bars represent ± SD; *P , 0.05.
Abbreviations: hPβCD, hydroxypropyl-β-cyclodextrin; NS, nanospheres; PI, polydispersity index; PLGA, Poly(D,L-lactide-co-glycolide); PLGA–PEG, poly(D,L-lactide-co-
glycolide) with poly(ethylene glycol); SD, standard deviation; ζ-pot, zeta potential.
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NSs were stored at 4°C, 25°C, and 40°C. After 6 months 
of storage, three samples of each lyophilized NS 
formulation were reconstituted and the physicochemical 
properties and the entrapment efficiency were determined. 
All formulations maintained their initial properties 
(P . 0.05) and could be easily resuspended by manual 
shacking after 6 months of storage at 4°C, 25°C, and 
40°C (Figure 5).
The stability of the rehydrated NSs powders was 
determined at 4°C, 25°C, and 40°C for 3 months of storage. 
Only formulations stored at 4°C remained unchanged in the 
aqueous form (P . 0.05). A slight increase in particle size 
and a decrease in zeta potential values were found for NSs 
stored at 25°C, which remained still suitable for ophthalmic 
administration at this temperature. However, a significant 
aggregation of the NSs was found at 40°C (P , 0.05). At 
this temperature, polymers were in the rubbery state. In this 
state, a polymer is at a higher free energy level than in its 
glassy state and thus is more reactive and the degradation is 
faster. A progressive decrease in pH values and an increase 
of tonicity appeared in the formulations stored at 40°C, 
which could be related to the oligomers release by polymer 
hydrolysis.60
Thermal properties were determined during storage 
conditions. As shown in Figure 6, no endothermic peak 
corresponding to the drug melting was detected in dried 
formulations stored for 6 months at 4°C and rehydrated and 
stored for 3 months at the same temperature.
Conclusion
In this work, we report the possibility of combining the 
advantages of polymeric NSs in terms of increasing FB 
permeability through corneal epithelium with the solubiliz-
ing properties of HPβCD in order to be an effective system 
for increasing the bioavailability of FB. Freeze-drying and 
sterilization of these formulations by a suitable method is 
often problematic. This work demonstrates that HPβBC is a 
suitable cryoprotectant in order to maintain the properties of 
the NSs developed and γ-irradiation allows sterile formula-
tions to be obtained for ophthalmic administration preventing 
contamination of these formulations.
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